Overview

Safety Study of AMG 228 to Treat Solid Tumors

Status:
Terminated

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Amgen